Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression

Recruiting in Palo Alto (17 mi)

Overseen byDavid Bond, MD

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of British Columbia

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

Depression is a medical condition characterized by feeling sad even when good things happen, having low energy and motivation, and sometimes even experiencing suicidal thoughts. Bipolar II Disorder is an illness in which periods of depression alternate with periods of abnormally elevated mood, energy and activity, referred to as hypomania. After Major Depressive Disorder, Bipolar II Disorder is the most common cause of depression. Unfortunately, antidepressant medications, used alone, do not work as well in treating Bipolar depression as they do in treating other kinds of depression. Lamotrigine is a medication which studies show is effective in treating Bipolar depression. The investigators will determine if lamotrigine works best to treat Bipolar II depression if it is used alone, or if it is taken with an antidepressant. In the first part of our investigation, people with Bipolar II depression who have not responded to an antidepressant will either add lamotrigine to their antidepressant, or will stop the antidepressant and take lamotrigine alone. They will see the study doctor for 6 visits over 8 weeks, and will answer questions about their depressive symptoms and their overall health. The purpose of this study phase is to determine which treatment works best to treat active Bipolar depression. In the second part of the study, people who have responded to their assigned treatment may continue to receive it for another 44 weeks. They will see the study doctor monthly, and will answer similar questions about their health. Participants will also receive a physical examination and get a blood test three times during the study. The purpose of the second phase is to ascertain which treatment is best at preventing relapses of depression. The investigators hypothesize that people who take Lamotrigine plus an antidepressant will recover from their depression more completely, have a longer period of wellness, and have better quality of life compared to those taking Lamotrigine alone.

Research Team

David Bond, MD

Principal Investigator

University of British Columbia

Lakshmi Yatham, MD

Principal Investigator

University of British Columbia

Edwin Tam, MD

Principal Investigator

University of British Columbia

Mauricio Kunz, Dr.

Principal Investigator

University of British Columbia

Kyooseob Ha, Dr.

Principal Investigator

Seoul National University Bundang Hospital

Wetid Pratoomsri, Dr.

Principal Investigator

Chachoengsao Hospital Thailand

Eligibility Criteria

Inclusion Criteria

Males or females, inpatients or outpatients, aged 17 to 70 years inclusive.

Diagnosis of Bipolar II Disorder, current episode depressed, without psychotic features. Specifically, patients must have experienced at least one previous episode of hypomania lasting at least 2 days, and no previous manic episodes.

The current episode of depression has a duration of at least 6 weeks.

See 2 more

Treatment Details

Interventions

Lamotrigine (Anti-epileptic drug)

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Lamotrigine Plus AntidepressantExperimental Treatment1 Intervention

Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.

Group II: 2. Lamotrigine MonotherapyActive Control1 Intervention

Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.